DedrickRM, Guerrero-BustamanteCA, GarlenaRA, et al.Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med, 2019; 25:730–733.
2.
FabijanAP, Ben ZakourNL, HoJ, et al.Polyclonal Staphylococcus aureus bacteremia. Ann Intern Med, 2019.
3.
GilbeyT, HoJ, CooleyLA, et al.Adjunctive bacteriophage therapy for prosthetic valve endocarditis due to Staphylococcus aureus. Med J Aust, 2019; 211:142–143 e141.
4.
MaddocksS, FabijanAP, HoJ, et al.Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med, 2019; 200:1179–1181.
5.
Petrovic FabijanA, LinRCY, HoJ, et al.Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat Microbiol, 2020; 5:465–472.
6.
JaultP, LeclercT, JennesS, et al.Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis, 2019; 19:35–45.
7.
ClementeA, RamsdenJJ, WrightA, et al.Staphylococcus aureus resists UVA at low irradiance but succumbs in the presence of TiO2 photocatalytic coatings. J Photochem Photobiol B, 2019; 193:131–139.
8.
VinnerGK, RichardsK, LeppanenM, et al.Microencapsulation of enteric bacteriophages in a pH-responsive solid oral dosage formulation using a scalable membrane emulsification process. Pharmaceutics, 2019; 11:475.
9.
VinnerGK, Rezaie-YazdiZ, LeppanenM, et al.Microencapsulation of salmonella-specific bacteriophage felix O1 using spray-drying in a pH-responsive formulation and direct compression tableting of powders into a solid oral dosage form. Pharmaceuticals (Basel), 2019; 12:43.
10.
SchulferA, Santiago-RodriguezTM, LyM, et al.Fecal viral community responses to high-fat diet in mice. mSphere, 2020; 5:e00833-19.
11.
MathieuA, DionM, DengL, et al.Virulent coliphages in 1-year-old children fecal samples are fewer, but more infectious than temperate coliphages. Nat Commun, 2020; 11:378.
12.
Del CoglianoME, PintoA, GoldsteinJ, et al.Relevance of bacteriophage 933W in the development of hemolytic uremic syndrome (HUS). Front Microbiol, 2018; 9:3104.
13.
AdhyaS, MerrilCR, BiswasB. Therapeutic and prophylactic applications of bacteriophage components in modern medicine. Cold Spring Harb Perspect Med, 2014; 4:a012518.
14.
SacherJC. How can phage companies protect their intellectual property?. Capsid Tail, 2020; 60.
15.
YenM, CairnsLS, CamilliA. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nat Commun, 2017; 8:14187.
16.
TolenTN, XieY, HairgroveTB, et al.Evaluation of commercial prototype bacteriophage intervention designed for reducing O157 and non-O157 shiga-toxigenic Escherichia coli (STEC) on beef cattle hide. Foods, 2018; 7:114.
